throbber
8/16/22, 11:24 AM
`
`Dr. Reddy's Laboratories Enters Into a Licensing Agreement to Obtain Rights for the Private Label Version of Lumify in the US
`
`
`
`
`
`
`
`08.01.2022
`Dr. Reddy's Laboratories Enters Into a Licensing Agreement to Obtain
`Rights for the Private Label Version of Lumify in the US
` |
`
`Dr. Reddyʼs Laboratories, along with its subsidiaries, announced it has entered into a licensing
`agreement with Princeton, New Jersey-based Slayback Pharma to acquire rights in Slaybackʼs
`Brimonidine Tartrate Ophthalmic Solution 0.025%, the private label equivalent of Lumify in
`United States. Lumify (Bausch + Lomb) is an over-the-counter (OTC) eye drop that can be used
`to relieve redness of the eye due to minor eye irritations. The agreement also provides Dr.
`Reddyʼs exclusive rights to the product outside the US.
`
`Slayback Pharma is the first company to file an abbreviated new drug application for the
`private label equivalent for Lumify with the FDA under Paragraph IV certification. The
`abbreviated NDA is currently under FDA review and covers Brimonidine Tartrate Ophthalmic
`Solution 0.025% in 2.5 ml and 7.5 ml fill volumes.
`
`“We are pleased to license this important OTC ophthalmic product for the U.S. market,” Marc
`Kikuchi, Chief Executive Oicer, North America Generics, Dr. Reddyʼs, said in a company news
`release. “This product complements Dr. Reddyʼs growing OTC product portfolio in the eye care
`category that includes the private label versions of Pataday Once Daily Relief and
`Pataday Twice Daily Relief.”
`
`https://eyewire.news/news/dr-reddys-laboratories-enters-into-a-licensing-agreement-to-obtain-rights-for-the-private-label-version-of-lumify-in-the-us?c4… 1/4
`
`Eye Therapies Exhibit 2097, 1 of 4
`Slayback v. Eye Therapies - IPR2022-00142
`
`Menu
`Search
`Share
`Copy Link
`

`

`8/16/22, 11:24 AM
`
`Dr. Reddy's Laboratories Enters Into a Licensing Agreement to Obtain Rights for the Private Label Version of Lumify in the US
`
`08.15.2022
`Opthea Announces Financing Deals for OPT-302 in Wet AMD
`Eyewire News
`
`How to Diagnose and Treat Nocturnal Lagophthalmos
`ack e Ga ch, OD, AAO, and es e O De , OD, AAO
`Eyetube
`
`08.08.2022
`Clearside Biomedical Enters Into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for
`Up to $65 Million
`Eyewire News
`
`https://eyewire.news/news/dr-reddys-laboratories-enters-into-a-licensing-agreement-to-obtain-rights-for-the-private-label-version-of-lumify-in-the-us?c4… 2/4
`
`Eye Therapies Exhibit 2097, 2 of 4
`Slayback v. Eye Therapies - IPR2022-00142
`
`More in Business
`Next Article
`

`

`Dr. Reddy's Laboratories Enters Into a Licensing Agreement to Obtain Rights for the Private Label Version of Lumify in the US
`
`8/16/22, 11:24 AM
`07.29.2022
`Lenstec Receives FDA Approval for the SBL-3 Multifocal IOL
` |
`
`Lenstec Announced that its SBL-3 IOL has been approved by the FDA. The SBL-3 IOL
`(Segmented Bifocal Lens) is a next generation asymmetric multifocal refractive IOL
`that provides patients with near, intermediate and distance vision. Its patented design allows
`for improved contrast sensitivity and minimized halo and glare (dysphotopsias) commonly
`associated with other traditional 'concentric ring' multifocal IOLs, according to a company
`news release.
`
`The segmented optic design is the first of its kind in the US. Lenstec's patented four point
`fixation and design allow surgeons confidence in the IOLs eective lens position within the
`capsule. Its availability in 0.25 diopter power increments, along with tolerances (+/- 0.11
`diopters from labeled power), assists surgeons in achieving the best refractive outcomes
`possible.
`
`"SBL 3 lens patients reported high quality distance and near vision, without the headache of
`severe dysphotopsia issues, and we had no complaints with computer vision," James Loden,
`MD, a principal investigator in the FDA trial, said in the news release.
`
`Sebastian Heersink, MD, another FDA trial principal investigator, stated, "In my own experience
`with the SBL-3, I have been very impressed with the quality and range of functional vision
`patients obtained, as well as their overall happiness. It performs well in low lighting and
`patients report excellent night driving. It's a great lens that I wouldn't hesitate to have
`implanted in my own eyes."
`
`https://eyewire.news/news/dr-reddys-laboratories-enters-into-a-licensing-agreement-to-obtain-rights-for-the-private-label-version-of-lumify-in-the-us?c4… 3/4
`
`Eye Therapies Exhibit 2097, 3 of 4
`Slayback v. Eye Therapies - IPR2022-00142
`
` Share
` Copy Link
`

`

`8/16/22, 11:24 AM
`
`Dr. Reddy's Laboratories Enters Into a Licensing Agreement to Obtain Rights for the Private Label Version of Lumify in the US
`
`08.16.2022
`First SBL-3 ClearView Multifocal Intraocular Lens Implanted in US
`Eyewire News
`
`08.16.2022
`Sight Sciences Announces Long Term Safety and Eectiveness Data of Standalone Use of the Omni Surgical
`System in Patients with Open Angle Glaucoma
`Eyewire News
`
`0 16 2022
`First Patients Treated with Lensar's ALLY Adaptive Cataract Treatment System
`Eyewire News
`
`ABOUT EYEWIRE+
`Eyewire+ keeps readers updated with the latest in the ophthalmic field, featuring breaking news from press
`eleases, medical journals, vision publications, videos, and other news sources
`
`
`
`GET EMAIL UPDATES
`
`FOLLOW US
`
`
`
`
`
`
`
`Advertising
`
`Privacy Policy
`
`© 2022 Bryn Mawr Commun cat ons LLC.
`A R ghts Reserved • Pr vacy Po cy
`
`https://eyewire.news/news/dr-reddys-laboratories-enters-into-a-licensing-agreement-to-obtain-rights-for-the-private-label-version-of-lumify-in-the-us?c4… 4/4
`
`Eye Therapies Exhibit 2097, 4 of 4
`Slayback v. Eye Therapies - IPR2022-00142
`
`More in Cataract
`Eyewire News
`EyewireTV
`Topics
`Events
`Send a Tip
`Contact
`About
`BMC Vision
`

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket